XML 58 R46.htm IDEA: XBRL DOCUMENT v3.21.1
License Agreements - Novartis (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 137 Months Ended
Apr. 30, 2016
Sep. 30, 2014
Jan. 31, 2010
Dec. 31, 2009
Nov. 30, 2009
Mar. 31, 2021
Mar. 31, 2020
Mar. 31, 2021
Dec. 31, 2020
License agreements                  
Revenues           $ 604,718 $ 568,507    
JAKAFI                  
License agreements                  
Revenues           465,710 459,479    
Novartis                  
License agreements                  
Upfront and immediate milestone payment to be received under license agreement         $ 210,000        
Upfront payment received under license agreement       $ 150,000          
Immediate milestone payment received under license agreement     $ 60,000            
Royalties payable           101,600   $ 101,600 $ 96,400
Reimbursable costs included in accounts receivable           100   100 $ 200
Research and development expenses reimbursed           100 300    
Novartis | Pre-specified Events | Maximum                  
License agreements                  
Upfront and immediate milestone payment to be received under license agreement         1,200,000        
Novartis | Development Milestones                  
License agreements                  
Amount recognized and received for the achievement of a predefined milestone               157,000  
Novartis | Development Milestones | Maximum                  
License agreements                  
Upfront and immediate milestone payment to be received under license agreement         174,000        
Novartis | Regulatory Milestones                  
License agreements                  
Amount recognized and received for the achievement of a predefined milestone               280,000  
Novartis | Regulatory Milestones | Maximum                  
License agreements                  
Upfront and immediate milestone payment to be received under license agreement         495,000        
Novartis | Sales and Commercial Milestones                  
License agreements                  
Amount recognized and received for the achievement of a predefined milestone               $ 200,000  
Novartis | Sales and Commercial Milestones | Maximum                  
License agreements                  
Upfront and immediate milestone payment to be received under license agreement         $ 500,000        
Novartis | Development and Commercialization Milestones                  
License agreements                  
Revenues           0 0    
Novartis | TABRECTA                  
License agreements                  
Revenues           $ 2,000 0    
Novartis | TABRECTA | Minimum                  
License agreements                  
Royalty payments on future global net sales (as a percent)           12.00%      
Novartis | TABRECTA | Maximum                  
License agreements                  
Royalty payments on future global net sales (as a percent)           14.00%      
Novartis | GVHD | Development and Regulatory Milestones | Maximum                  
License agreements                  
Upfront and immediate milestone payment to be received under license agreement $ 75,000                
Novartis | JAKAFI | U.S.                  
License agreements                  
Royalties payable on net sales           $ 17,800 17,500    
Novartis | JAKAVI                  
License agreements                  
Revenues           $ 65,600 $ 56,300    
Novartis | JAKAVI | Regulatory Milestones | Europe                  
License agreements                  
Amount recognized and received for the achievement of a predefined milestone   $ 60,000